Abstract
We have not added the abstract for this paper yet. The publisher's page has the full record.
Complementary analyses of the AMBAR trial: Individual items of CDR and ADAS-Cog12 in Alzheimer's disease patients treated with plasma exchange with albumin replacement
Alzheimer's & Dementia · Vol. 17 Published January 1, 2021
More on these topics
Browse all publications →-
2020 · Alzheimer's & Dementia
Complementary analyses of the AMBAR trial: Impact of discontinuations, consistency of results across outcomes and additional adjustments
-
2026 · The Journal of Prevention of Alzheimer's Disease
Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s disease
-
2024 · Front Neurol
Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer's disease
-
2022 · Neurology
Feasibility, Safety, and Efficacy of Gamma Sensory Stimulation as a Novel Therapeutic Intervention for Alzheimer's Disease (N1. 001)